Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ovarian Cancer: Update Bulletin # 2 [October 2018]

Product Code:
596201005
Publication Date:
October 2018
Format:
PDF
Price:
$1,095

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the ovarian cancer market. KOLs provided their candid insights on key events, including: AstraZeneca and Merck & Co.’s presentation of positive data from the SOLO-1 trial of Lynparza (olaparib) as a first-line maintenance therapy, for BRCA1/2-mutated advanced ovarian cancer, at ESMO 2018; the EMA’s validation of Clovis’ application to extend the approval of Rubraca (rucaparib) to include the maintenance treatment of patients with recurrent ovarian cancer who are in a complete or partial response to platinum-based chemotherapy; the publication of positive data from a Phase II trial of AstraZeneca’s mTOR inhibitor vistusertib, in combination with paclitaxel, in patients with advanced ovarian cancer.

Business Questions:

• Will the SOLO-1 trial position Lynparza as a new standard of care for the first-line maintenance treatment of BRCA-mutated ovarian cancer?
• How do KOLs regard the magnitude of benefit seen in the SOLO-1 trial of Lynparza?
• What questions remain regarding the potential efficacy of Lynparza as a first-line maintenance therapy?
• How do KOLs view the tolerability of Lynparza in the first-line maintenance setting, and do the benefits outweigh the risks?
• How do KOLs react to the EU validation of Clovis’ application for Rubraca’s label to include maintenance therapy in recurrent disease?
• Will Clovis be successful in securing EU approval of Rubraca in the maintenance treatment of recurrent ovarian cancer, and how do KOLs view the supporting data from the ARIEL3 trial?
• What is the overall outlook for Rubracaas a maintenance therapy for recurrent disease?
• How will oncologists choose between PARP inhibitors as maintenance therapy in recurrent ovarian cancer?
• How do KOLs view early data for AstraZeneca’s mTOR inhibitor vistusertib, in combination with paclitaxel, for patients with advanced ovarian cancer?• What is the overall outlook for mTOR inhibitors in the treatment of ovarian cancer?

 




customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved